Who to call at Dyne Therapeutics, Inc., and when
Fundz watches for the moments Dyne Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Dyne Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Dyne Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Dyne Therapeutics, Inc.. With Fundz connected, it knows.
Dyne Therapeutics, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
dyne-tx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Dyne Therapeutics disclosed new one-year clinical data from its Phase 1/2 ACHIEVE trial evaluating zeleciment basivarsen (DYNE-101) for myotonic dystrophy type 1, along with baseline video hand-opening time metrics for the registrational expansion cohort, signaling progress in its clinical development pipeline.
Key Takeaways
One-year clinical data from the MAD portion of the Phase 1/2 ACHIEVE trial has been disclosed, demonstrating continued progress in DYNE-101 development
Mean baseline video hand-opening time (vHOT) values were announced for the registrational expansion cohort, providing key efficacy measurement data
2 more takeaways
Related Filings (2)
2 more filings from Dyne Therapeutics, Inc. in the last 90 days
Filing Overview
What This Means
Dyne Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.